Leaders expand their product delivery approach to boost access for lower-income countries
Novartis leads the way as the only company that implements an equitable strategy in lower-income countries for all products analysed. Overall, Novartis and GSK target multiple countries and patient populations across the income pyramid with their access strategies, e.g., equitable pricing and responsible IP management. Furthermore, they both leverage their know-how and resources to address local access barriers through their capacity building initiatives.
1 | Novartis AG |
0
1
2
3
4
5
|
4.53 | |
Novartis AGRead more |
||||
2 | GlaxoSmithKline plc |
0
1
2
3
4
5
|
4.36 | |
GlaxoSmithKline plcRead more |
||||
3 | Pfizer Inc. |
0
1
2
3
4
5
|
3.91 | |
Pfizer Inc.Read more |
||||
3 | Sanofi |
0
1
2
3
4
5
|
3.91 | |
SanofiRead more |
||||
4 | Novo Nordisk A/S |
0
1
2
3
4
5
|
3.81 | |
Novo Nordisk A/SRead more |
||||
5 | Johnson & Johnson |
0
1
2
3
4
5
|
3.78 | |
Johnson & JohnsonRead more |
||||
6 | AstraZeneca plc |
0
1
2
3
4
5
|
3.29 | |
AstraZeneca plcRead more |
||||
7 | Takeda Pharmaceutical Co. Ltd. |
0
1
2
3
4
5
|
3.22 | |
Takeda Pharmaceutical Co. Ltd.Read more |
||||
8 | Merck KGaA (Merck) |
0
1
2
3
4
5
|
3.16 | |
Merck KGaA (Merck)Read more |
||||
9 | Boehringer Ingelheim GmbH |
0
1
2
3
4
5
|
3.09 | |
Boehringer Ingelheim GmbHRead more |
||||
10 | Eisai Co. Ltd. |
0
1
2
3
4
5
|
3.06 | |
Eisai Co. Ltd.Read more |
||||
11 | Bayer AG |
0
1
2
3
4
5
|
3.03 | |
Bayer AGRead more |
||||
12 | Roche Holding AG |
0
1
2
3
4
5
|
2.92 | |
Roche Holding AGRead more |
||||
13 | Gilead Sciences Inc. |
0
1
2
3
4
5
|
2.50 | |
Gilead Sciences Inc.Read more |
||||
14 | Astellas Pharma Inc. |
0
1
2
3
4
5
|
2.35 | |
Astellas Pharma Inc.Read more |
||||
15 | Daiichi Sankyo Co. Ltd. |
0
1
2
3
4
5
|
1.90 | |
Daiichi Sankyo Co. Ltd.Read more |
||||
16 | Merck & Co., Inc. (MSD) |
0
1
2
3
4
5
|
1.82 | |
Merck & Co., Inc. (MSD)Read more |
||||
17 | AbbVie Inc. |
0
1
2
3
4
5
|
1.30 | |
AbbVie Inc.Read more |
||||
18 | Eli Lilly & Co. |
0
1
2
3
4
5
|
1.25 | |
Eli Lilly & Co.Read more |
||||
19 | Bristol Myers Squibb Co. |
0
1
2
3
4
5
|
1.15 | |
Bristol Myers Squibb Co.Read more |
0
1
2
3
4
5
|
The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.